Rimonabant

CHEMBL111 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

463.8 g/mol

LogP

6.5

Phase

4

Rimonabant is a selective cannabinoid CB1 receptor inverse agonist that blocks the endocannabinoid system's orexigenic (appetite-stimulating) and metabolic effects in both the hypothalamus and peripheral tissues, reducing food intake and improving metabolic parameters including obesity and dyslipidemia. It was withdrawn from the European market due to serious psychiatric adverse effects including depression, anxiety, and suicidal ideation.

Molekularmasse

463,8000 g/mol

LogP

6,50

TPSA

50,20 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Cardiovascular Disease Pain Management Schizophrenia Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

InChI

InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)

Molecular Formula

C22H21Cl3N4O

HBD / HBA

1 / 3

Rotierbare Bindungen

4

Schwere Atome

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Rimonabant is a selective cannabinoid CB1 receptor inverse agonist that blocks the endocannabinoid system's orexigenic (appetite-stimulating) and metabolic effects in both the hypothalamus and peripheral tissues, reducing food intake and improving metabolic parameters including obesity and dyslipidemia. It was withdrawn from the European market due to serious psychiatric adverse effects including depression, anxiety, and suicidal ideation.

Yes, Rimonabant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL111. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 104850. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Rimonabant auf PillFYI

Struktur

Schnelldaten

Formel: C22H21Cl3N4O

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.